Roivant Sciences Ltd. $ROIV Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 90.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 80,561 shares of the company’s stock after acquiring an additional 38,354 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Roivant Sciences were worth $1,746,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Jones Financial Companies Lllp grew its position in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares in the last quarter. Allworth Financial LP boosted its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Bessemer Group Inc. increased its stake in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Roivant Sciences by 204.2% during the second quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock worth $65,000 after purchasing an additional 3,882 shares during the period. Finally, Aster Capital Management DIFC Ltd raised its holdings in shares of Roivant Sciences by 75.8% during the third quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock worth $67,000 after purchasing an additional 1,900 shares during the period. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ROIV. Guggenheim raised their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 9th. HC Wainwright boosted their price objective on Roivant Sciences from $33.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Citigroup raised their target price on Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Piper Sandler upped their price target on shares of Roivant Sciences from $22.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 16th. Finally, TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research report on Wednesday, March 4th. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $30.55.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the sale, the chief executive officer directly owned 1,654,597 shares in the company, valued at $43,830,274.53. This represents a 10.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mayukh Sukhatme sold 339,441 shares of Roivant Sciences stock in a transaction on Monday, February 9th. The shares were sold at an average price of $26.47, for a total value of $8,985,003.27. Following the transaction, the insider owned 19,148,664 shares in the company, valued at approximately $506,865,136.08. This trade represents a 1.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 5,085,398 shares of company stock valued at $139,215,946. 10.80% of the stock is currently owned by insiders.

Roivant Sciences Stock Down 2.5%

ROIV stock opened at $27.83 on Friday. The company has a 50-day simple moving average of $28.30 and a 200 day simple moving average of $23.90. The company has a market capitalization of $19.92 billion, a P/E ratio of -23.79 and a beta of 1.14. Roivant Sciences Ltd. has a fifty-two week low of $10.58 and a fifty-two week high of $30.33.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.